P. Koralewski

11.3k total citations · 6 hit papers
58 papers, 7.1k citations indexed

About

P. Koralewski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P. Koralewski has authored 58 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in P. Koralewski's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (13 papers) and Renal cell carcinoma treatment (12 papers). P. Koralewski is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (13 papers) and Renal cell carcinoma treatment (12 papers). P. Koralewski collaborates with scholars based in Poland, United Kingdom and France. P. Koralewski's co-authors include Carsten Bokemeyer, Igor Bondarenko, Filippo de Braud, Angela Zubel, Gunter Schuch, Cezary Szczylik, Bernard Escudier, Alain Ravaud, A Płużańska and Bohuslav Melichar and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

P. Koralewski

57 papers receiving 6.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

2008 1.2k citations Carsten Bokemeyer, Igor Bondarenko et al. Journal of Clinical Oncology profile →
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 734 citations Ricardo Hitt, P. Koralewski et al. Journal of Clinical Oncology profile →
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 612 citations Carsten Bokemeyer, Igor Bondarenko et al. Annals of Oncology profile →
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

2000 606 citations Jacques Bonneterre, Beat Thürlimann et al. Journal of Clinical Oncology profile →
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations M. M. Heiss, P. Koralewski et al. profile →

Peers

Countries citing papers authored by P. Koralewski

Since Specialization

Citations

This map shows the geographic impact of P. Koralewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Koralewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Koralewski more than expected).

Fields of papers citing papers by P. Koralewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Koralewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Koralewski. The network helps show where P. Koralewski may publish in the future.

Co-authorship network of co-authors of P. Koralewski

This figure shows the co-authorship network connecting the top 25 collaborators of P. Koralewski. A scholar is included among the top collaborators of P. Koralewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Koralewski. P. Koralewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial 2022 ·European Urology ·Sumanta K. Pal, Javier Puente, Daniel Yick Chin Heng, Hilary Glen, P. Koralewski, Daniil Stroyakovskiy, B. Yа. Alekseev, Francis Parnis, Daniel Castellano, Tudor–Eliade Ciuleanu, Jae‐Lyun Lee, Kaisa Sunela, (unknown), (unknown), (unknown), Alan D. Smith, Sun Young Rha	17
2	120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study 2021 ·Annals of Oncology ·James Chih‐Hsin Yang, Alexander Luft, Emmanuel de la Mora Jimenez, Jun S. Lee, P. Koralewski, Nuri Karadurmuş, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin, Julia Dudnik, (unknown), Tarek Mekhail, Chinyere E. Okpara, Zachary Zimmer, Ayman Samkari, Niyati Bhagwati, Tibor Csőszi	18
3	LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 2021 ·Annals of Oncology ·Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Robert L. Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, (unknown), Nabil F. Saba, Milena Perez Mak, Miguel Ángel Álvarez-Avitia, Alexander Guminski, Urs Müller‐Richter, Naomi Kiyota, Mustimbo Roberts, (unknown), (unknown), Wei Li, (unknown)	21
4	1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial 2020 ·Annals of Oncology ·P. Clingan, Daniel Brungs, Rahul Ladwa, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, P. Koralewski, Iwona Ługowska, Chaiyut Charoentum, Arunee Dechaphunkul, Virote Sriuranpong, (unknown), (unknown)	6
5	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study breakdown → 2011 ·Annals of Oncology ·Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann, Filippo de Braud, Gunter Schuch, Angela Zubel, İ. Çelik, M. Schlichting, P. Koralewski	612
6	Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck 2010 ·Annals of Oncology ·Ricard Mesı́a, Fernando Rivera, Andrzej Kawecki, Sylvie Rottey, Ricardo Hitt, H. Kienzer, Didier Cupissol, D. De Raucourt, Marco Benasso, P. Koralewski, J.P. Delord, Carsten Bokemeyer, Desmond Curran, Andrew Gross, J. B. Vermorken	78
7	A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients 2008 ·Annals of Oncology ·Xavier Pivot, P. Koralewski, Jorge Hidalgo, Arlene Chan, Anthony Gonçalvès, Gilberto Schwartsmann, Sylvie Assadourian, Jean‐Pierre Lotz	148
8	First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma 2008 ·Annals of Oncology ·Bohuslav Melichar, P. Koralewski, Alain Ravaud, A Płużańska, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, R. Delva, Emmanuel Sevin, Sylvie Négrier, J McKendrick, Armando Santoro, Pavel Pisa, Bernard Escudier	71
9	Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer 2008 ·Cancer Chemotherapy and Pharmacology ·Mario Campone, Maria Błasińska-Morawiec, (unknown), P. Koralewski, Jean-Christophe Pouget, (unknown), Maud Brandely	7
10	Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer 2008 ·Annals of Oncology ·David Cunningham, Bhawna Sirohi, A Płużańska, B. Utracka-Hutka, J. Załuski, Rob Glynne‐Jones, P. Koralewski, John Bridgewater, Paul N. Mainwaring, Harpreet Wasan, (unknown), Cezary Szczylik, P. Clingan, (unknown), Isabelle Tabah-Fisch, Jim Cassidy	48
11	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma 2008 ·Journal of Clinical Oncology ·Daniel G. Haller, Mace L. Rothenberg, A. Wong, P. Koralewski, Wilson H. Miller, G. Bodoky, Nassir Habboubi, Carlos A. Garay, (unknown)	40
12	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial breakdown → 2007 ·The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore	1722
13	5001 ORAL Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study 2007 ·European Journal of Cancer Supplements ·S. Parsons, E. Kutarska, P. Koralewski, (unknown), Pauline Wimberger, Alexander Burges, (unknown), (unknown), (unknown), (unknown)	1
14	Small-Cell Lung Cancer Diagnostic and Therapeutic Recommendations of Polish Lung Cancer Group 2007 ·Advances in respiratory medicine ·Maciej Krzakowski, Tadeusz Orłowski, Kazimierz Roszkowski, Marian Reinfuss, Włodzimierz Olszewski, Rodryg Ramlau, Dariusz M. Kowalski, Krzysztof Konopa, Jacek Jassem, Renata Jankowska, Jerzy Kozielski, Marek Z. Wojtukiewicz, Kazimierz Drosik, P. Koralewski	0
15	Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study 2007 ·Journal of Clinical Oncology ·SL Parsons, E. Kutarska, P. Koralewski, M. Gore, Pauline Wimberger, Alexander Burges, (unknown), Angelika Lahr, (unknown), M. M. Heiss	11
16	Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non–Small-Cell Lung Cancer 2006 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Jean‐Yves Douillard, P. Koralewski, Christian Manegold, Egbert F. Smit, Jose Reyes, Gee‐Chen Chang, William J. John, Patrick Peterson, Coleman K. Obasaju, Michael Lahn, David R. Gandara	127
17	Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial 2003 ·Annals of Oncology ·Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves	222
18	Efficacy and safety of ITS fentanyl given directly after tramadol to patients withcancer related pain (based on FEN-POL-2 trial) 2002 ·Nowotwory Journal of Oncology ·J Łuczak, (unknown), Rodryg Ramlau, Marek Z. Wojtukiewicz, P. Koralewski, Maciej Krzakowski, J. Załuski	2
19	Oral vinorelbine: Feasibility and safety profile 2001 ·Annals of Oncology ·A Depierre, Gilles Freyer, Jacek Jassem, Hubert Orfeuvre, Rodryg Ramlau, É. Lemarié, P. Koralewski, L. Mauriac, Jean-Luc Breton, T. Delozier, V. Trillet-Lenoir	42
20	Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study breakdown → 2000 ·Journal of Clinical Oncology ·Jacques Bonneterre, Beat Thürlimann, J.F.R. Robertson, Maciej Krzakowski, L. Mauriac, P. Koralewski, Ignace Vergote, Alan Webster, Mark L. Steinberg, Mia von Euler	606

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact